These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 10584440

  • 21. The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.
    Archer DF.
    Menopause; 2011 Jan; 18(1):6-7. PubMed ID: 21173718
    [No Abstract] [Full Text] [Related]

  • 22. Breast cancer risk reduction: what do we know and where should we go?
    Prout MN.
    Medscape Womens Health; 2000 Jan; 5(5):E4. PubMed ID: 11113777
    [Abstract] [Full Text] [Related]

  • 23. Moving forward with breast cancer prevention.
    Chen WY, Rosner B, Colditz GA.
    Cancer; 2007 Jun 15; 109(12):2387-91. PubMed ID: 17464950
    [No Abstract] [Full Text] [Related]

  • 24. Summaries for patients. Using medications to decrease the risk for breast cancer in women: recommendations from the U.S. Preventive Services Task Force.
    Ann Intern Med; 2013 Nov 19; 159(10):I-28. PubMed ID: 24400336
    [No Abstract] [Full Text] [Related]

  • 25. Two good choices to prevent breast cancer: great taste, less filling.
    Hortobagyi GN, Brown PH.
    Cancer Prev Res (Phila); 2010 Jun 19; 3(6):681-5. PubMed ID: 20522797
    [Abstract] [Full Text] [Related]

  • 26. [Chemoprevention of breast cancer. Clinical trials in pharmacological prevention].
    Ricart JJ.
    Medicina (B Aires); 2004 Jun 19; 64(1):66-72. PubMed ID: 15034961
    [Abstract] [Full Text] [Related]

  • 27. Lowering your breast cancer risk. A daily pill can hold the key to prevention for some women.
    Johns Hopkins Med Lett Health After 50; 2014 Feb 19; 25(15):1-2. PubMed ID: 25118364
    [No Abstract] [Full Text] [Related]

  • 28. Similarity of uterine mucosa changes in patients treated by raloxifen and tamoxifen.
    Willèn R, Willèn H, Lindahl B.
    Anticancer Res; 2002 Feb 19; 22(2B):1121-5. PubMed ID: 12168910
    [Abstract] [Full Text] [Related]

  • 29. [Additional effect of SERM: mammary gland].
    Kurebayashi J.
    Clin Calcium; 2004 Oct 19; 14(10):47-51. PubMed ID: 15577131
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).
    Powles TJ.
    Breast Cancer Res; 2006 Oct 19; 8(5):111. PubMed ID: 17049068
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.
    Curr Med Res Opin; 2008 Mar 19; 24(3):807-13. PubMed ID: 18254988
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A reconsideration of tamoxifen use for breast cancer.
    Wang PH, Chao HT.
    Taiwan J Obstet Gynecol; 2007 Jun 19; 46(2):93-5. PubMed ID: 17638615
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.